SeaStar Medical Holding Corpora
0.5699-0.00 (-0.35%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · ICU · USD
Key Stats
Market Cap
19.43MP/E (TTM)
-Basic EPS (TTM)
-1.85Dividend Yield
0%Recent Filings
8-K
Exec salary hikes approved
SeaStar Medical Holding Corporation's board approved salary increases for CEO Eric Schlorff and CMO Kevin Chung, plus other executives, effective October 1, 2025, reversing a 20% cut from June 2025 aimed at slashing costs. Directors' cash retainers also return to original levels. This boosts monthly operating expenses by about $50,000. Expenses rise, yet leadership stays incentivized.
8-K
CFO termination and interim appointments
SeaStar Medical terminated CFO David Green without cause effective August 14, 2025, triggering ~$300,000 in severance over 12 months, COBRA coverage for 18 months, and accelerated RSU vesting. CEO Eric Schlorff stepped in as interim CFO on August 19, while Controller Bradford Towne, with prior roles at Aytu BioPharma and Gevo, became principal accounting officer. Leadership shuffle adds interim uncertainty amid the CFO search.
8-K
Q2 revenue up, trial advances
SeaStar Medical reported Q2 2025 net revenue of $0.3 million from QUELIMMUNE sales, slashing net loss to $2.0 million from $3.2 million year-over-year, while boosting cash to $6.3 million via $12.4 million in offerings. The NEUTRALIZE-AKI trial hit 125 of 200 enrollments, with DSMB interim analysis due Q3 2025; three top children's hospitals adopted QUELIMMUNE, and SAVE Registry data showed 75% 28-day survival in 20 pediatric patients. Progress accelerates adult AKI market entry. Yet funding remains tight.
10-Q
Q2 FY2025 results
SeaStar Medical kicked off revenue in Q2 FY2025 with $338K from QUELIMMUNE sales, up from zero a year ago, while gross profit hit $311K on minimal costs. Operating expenses dropped sharply—R&D by 56% y/y to $1.0M, G&A by 56% to $1.0M—yielding a $1.8M operating loss, better than the $4.7M hit last year. Net loss narrowed to $2.0M from $3.2M, thanks to tamed fair-value swings on warrants, though other financing costs nipped $298K. Cash climbed to $6.3M on $10.1M in equity raises, wiping out debt; free cash flow not disclosed in the 10-Q. Yet Nasdaq's bid price warning signals delisting risk if shares don't rebound.
8-K
Resumes limited ATM stock sales
SeaStar Medical Holding Corporation resumed sales under its at-the-market offering agreement with H.C. Wainwright & Co., capping the aggregate offering price at $2,166,305 after suspending in July 2025 following $6.8 million in prior sales from the original $25 million program. The company plans to deploy any net proceeds for general corporate purposes, including working capital and capital expenditures, while retaining flexibility in allocation. No minimum sales are required. Proceeds will sit in safe investments until used.
CELZ
Creative Medical Technology Hol
3.76-1.83
CLCS
Cell Source, Inc.
0.38+0.03
CTSO
Cytosorbents Corporation
0.78-0.05
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ICCM
IceCure Medical Ltd.
0.75-0.02
ICUI
ICU Medical, Inc.
117.67-2.44
ISCO
International Stem Cell Corp.
0.15+0.00
SEM
Select Medical Holdings Corpora
14.28+0.06
SEPSF
ASEP Medical Holdings Inc.
0.39+0.00
SNWV
SANUWAVE Health, Inc.
30.44-0.60